Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of MK-6194 in adults with systemic lupus erythematosus
2023-505520-61-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing MK-6194 with Placebo for MK-6194 (2 arms). Primary endpoints: Percentage of participants achieving SRI-4 response at Week 28, Percentage of participants experiencing adverse events and 1 more. Started Feb 2024; status: completed.
02
Drugs
PT101
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2023-505520-61-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505520-61-00.